Endocrine disruptors – Recent policy developments and recommendations in the EU

In recent years, the Commission has taken steady actions and acted against EDs in line with the different requirements laid down in the relevant legislation. However, substances with endocrine disrupting properties are subject to case-by-case regulatory action on the basis of the general requirements of the legislation.

Are you ready for the upcoming deadline for the poison centre notifications of hazardous mixtures?

Importers and downstream users placing hazardous mixtures will have to provide specific information in a harmonized notification format to the relevant national appointed bodies, who will make this information available to poison centres so that they can provide rapid medical advice in the event of an emergency.

Adopting New Approach Methodologies (NAM) in the next generation risk assessment (NGRA)

The term “new approach methodologies” (NAMs) has been emerged as a descriptive reference to any non-animal-based approaches that can be used to provide information in the context of chemical hazard and risk assessment. These new approaches include integrated approaches to testing and assessment (IATAs), defined approaches for data interpretation, and performance-based evaluation of test methods.

Developments on the identification of potential endocrine disruptors under EU legislation

Introducing 2018 developments in EU policy and legislation on endocrine disruptors and our first experiences with the EFSA/ECHA guidance.

ECHA Public activities coordination tool

A new version of the Public activities coordination tool (PACT) has been integrated in the European Chemicals Agency (ECHA) website. This searchable and customizable database now includes substances for which dossier evaluation is ongoing and registries of CLP/restriction/SVHC intentions.

13th SETAC Scientific Symposium: Extrapolation of effects across biological levels

The symposium discussed extrapolation tools for environmental risk assessment purposes across different biological levels, and more importantly, how to bring those models to regulatory conformity.